Nanobiotix Joins Elite Index, Validating Physics-Based Cancer Fight

PARIS and CAMBRIDGE, Mass. – June 02, 2026 – In a move that underscores the growing intersection of technology and life sciences, Nanobiotix has been officially inducted into the Euronext Tech Leaders segment and its accompanying index. For the late-clinical stage biotechnology firm, this isn't just a symbolic accolade; it's a powerful validation of a radical idea: that the principles of physics can be harnessed to revolutionize cancer treatment. The inclusion elevates the Paris-based company into a select group of Europe’s most promising tech enterprises, promising to amplify its visibility among a global investor base that is increasingly hungry for disruptive innovation.

“Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities,” said Laurent Levy, chief executive officer of Nanobiotix, in a statement. “Our inclusion in the Euronext Tech Leaders segment recognizes not only the progress we have made as a company, but also the broader potential of physics-based innovation to contribute meaningfully to the future of healthcare.”

The Significance of a Tech Crown

Launched in 2022, the Euronext Tech Leaders initiative is more than a simple stock index. It is a curated ecosystem designed to spotlight and nurture Europe's most innovative and high-growth technology companies. With 113 members as of this month, the program acts as a catalyst, connecting these firms with international investors, strategic partners, and a suite of services aimed at accelerating their journey.

Entry into this exclusive club is governed by stringent criteria. Companies must not only be classified as a technology leader but also demonstrate a robust growth profile. To qualify, a firm with a market capitalization under €1 billion must show either a compound annual revenue growth rate of at least 20% over three years or have raised a minimum of €50 million in the same period. For Nanobiotix, which has successfully navigated the complex and capital-intensive world of drug development, meeting these benchmarks is a testament to both its scientific progress and its financial strategy. Inclusion provides tangible benefits, from enhanced exposure through index-linked ETFs and funds to access to exclusive investor forums, effectively placing the company on the radar of a much broader and more diverse pool of capital.

A Profile in Disruption

Nanobiotix’s ascent is built on the promise of its lead product candidate, NBTXR3. This first-in-class “nanoradioenhancer” is at the heart of the company’s clinical and commercial ambitions. The firm's progress has been methodical and impressive, marked by significant clinical milestones and strategic partnerships that have undoubtedly caught the attention of the Euronext selection committee.

The most prominent trial is NANORAY-312, a global Phase 3 study evaluating NBTXR3 in elderly patients with locally advanced head and neck cancer who are ineligible for platinum-based chemotherapy—a population with dire unmet needs. The therapy has already received Fast Track designation from the U.S. FDA for this indication, signaling its potential to address a serious condition. Beyond head and neck cancer, NBTXR3 secured a European CE mark in 2019 for treating soft tissue sarcoma, providing crucial regulatory validation. Furthermore, recent data from studies in non-small cell lung cancer and esophageal adenocarcinoma have shown promising early results, with high response rates and acceptable safety profiles.

This clinical momentum is underpinned by a landmark collaboration. In July 2023, Nanobiotix entered a global co-development and commercialization agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. This partnership not only provides significant financial backing through upfront and potential milestone payments but also lends the formidable development and commercial expertise of a pharmaceutical giant to the NBTXR3 program. Bolstered by this partnership and strong investor confidence, the company recently closed a global offering that raised approximately $100 million in late May, securing the resources needed to advance its ambitious pipeline.

Beyond Biology: The Physics of a Cure

What truly sets Nanobiotix apart is its foundational technology. The company operates at the nexus of nanotechnology, physics, and medicine, pioneering an approach that is distinct from traditional biological or chemical therapies. NBTXR3 consists of crystalline hafnium oxide nanoparticles designed to be injected once, directly into a tumor.

When exposed to standard radiotherapy, these nanoparticles use their physical properties to absorb and amplify the radiation dose within the tumor by a factor of up to nine. The effect is highly localized, dramatically increasing the destructive power of the radiation where it's needed most while sparing surrounding healthy tissue. After activation, the particles become inert, posing no further biological effect. This physical mode of action suggests a broad applicability across any solid tumor that can be treated with radiotherapy.

Perhaps most exciting is the technology's potential to transform immuno-oncology. By causing a more profound and immunogenic form of cancer cell death, NBTXR3-activated radiotherapy can release signals that alert and prime the patient’s own immune system. This has the potential to turn immunologically “cold” tumors, which are invisible to the immune system, into “hot” tumors that become vulnerable to attack. This could not only improve local tumor control but also trigger a systemic, body-wide anti-tumor response, potentially fighting metastatic disease and overcoming resistance to checkpoint inhibitor drugs.

The Investor's View: A Market Poised for Impact

For investors, the Euronext Tech Leaders inclusion serves as a powerful new data point. The company already enjoys a consensus “Buy” or “Moderate Buy” rating from analysts, who have been tracking its clinical progress and the unfolding potential of its platform. The successful $100 million offering in May, despite volatile market conditions, demonstrated significant institutional demand.

The new designation is expected to further enhance liquidity and attract a fresh wave of international investors, particularly those managing tech-focused funds and ETFs that track the Euronext Tech Leaders Index. It formally places Nanobiotix alongside Europe’s premier software, fintech, and digital media companies, acknowledging that the future of medicine is, in itself, a frontier of technology. This recognition validates the long-term vision of a company betting that the smallest particles can have the largest impact on human health.